Skip to main content
Symptom
dx.
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Symptom
dx.
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Get Started
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Loading...
Chylothorax
Cardiovascular Presentations
Abdominal aortic aneurysm
Acute coronary syndrome (NSTEMI)
Acute coronary syndrome (STEMI)
Acute decompensated heart failure
Acute limb ischemia
Acute mesenteric ischemia
Aortic dissection
Aortic stenosis
Atrial fibrillation and flutter
Bradyarrhythmia and heart block
Cardiac arrest
Deep vein thrombosis
Myocarditis
Pericarditis
Pulmonary embolism
Stable angina
Superficial thrombophlebitis
Superior vena cava syndrome
Supraventricular tachycardia
Syncope (cardiogenic)
Unstable angina
Ventricular tachycardia
Respiratory Presentations
Acute bronchitis
Acute respiratory failure
Aspiration pneumonia
Asthma exacerbation
Bronchiolitis
Community-acquired pneumonia
COVID-19 pneumonia
COPD exacerbation
Croup
Croup (laryngotracheobronchitis)
Epiglottitis
Hemothorax
Hospital-acquired pneumonia
Pleural effusion
Pneumothorax (traumatic)
Pulmonary contusion
Spontaneous pneumothorax
Neurological Presentations
Bell's palsy
Benign paroxysmal positional vertigo
Brain abscess
Cauda equina syndrome
Cervical radiculopathy
Concussion (mild traumatic brain injury)
Encephalitis
Guillain-Barré syndrome
Hemorrhagic stroke (intracerebral)
Ischemic stroke
Lumbar radiculopathy
Malignant spinal cord compression
Migraine
Peripheral neuropathy (acute)
Retropharyngeal abscess
Schizophrenia (acute exacerbation)
Seizure (breakthrough:known epilepsy)
Seizure (first-time)
Spinal cord injury
Status epilepticus
Subarachnoid hemorrhage
Tension headache
Transient ischemic attack
Traumatic brain injury (moderate-severe)
Vestibular neuritis
Viral meningitis
Gastrointestinal Presentations
Acute appendicitis
Acute cholecystitis
Acute diverticulitis
Acute pancreatitis
Anal fissure
Choledocholithiasis and cholangitis
Clostridioides difficile colitis
Gastritis
Gastroenteritis (viral and bacterial)
Gastroesophageal reflux disease
Incarcerated or strangulated hernia
Inflammatory bowel disease flare
Large bowel obstruction
Lower GI hemorrhage
Peptic ulcer disease
Perforated viscus
Small bowel obstruction
Upper GI hemorrhage
Genitourinary and Reproductive Presentations
Acute prostatitis
Acute urinary retention
Ectopic pregnancy
Epididymitis
Orchitis
Ovarian torsion
Paraphimosis
Pelvic inflammatory disease
Priapism
Pyelonephritis
Renal laceration
Ruptured ovarian cyst
Testicular torsion
Tubo-ovarian abscess
Urinary tract infection (uncomplicated)
Urolithiasis (renal colic)
Vaginal bleeding (non-pregnant)
Infectious Disease Presentations
Acute sinusitis
Acute tonsillitis
Acute upper respiratory infection
Animal bite
Bacterial meningitis
Cellulitis
Conjunctivitis (bacterial)
Dental abscess
Endocarditis
Febrile neutropenia
Fournier gangrene
Hand-foot-mouth disease
Hepatitis (acute)
Herpes zoster
HIV-related illness
Human bite
Impetigo
Infected diabetic foot ulcer
Infectious mononucleosis
Influenza
Necrotizing fasciitis
Osteomyelitis
Otitis externa
Parasitic infection
Periorbital cellulitis
Peritonsillar abscess
Scabies
Sepsis
Septic arthritis
Spontaneous bacterial peritonitis
Tick-borne illness (Lyme disease)
Tinea infection
Tuberculosis
Viral exanthem
Wound infection
Trauma Presentations
Achilles tendon rupture
ACL and mceniscus tear
Ankle fracture
Ankle sprain
Burn
Calcaneus fracture
Cervical spine fracture
Clavicle fracture
Dental avulsion
Distal radius fracture
Drowning
Elbow fracture and dislocation
Electrical injury
Facial bone fracture
Facial laceration
Femur fracture
Fingertip amputation
Forearm fracture (radius and ulna)
Frostbite
Hand:finger laceration
Heat exhaustion
Heat stroke
Hip fracture
Humeral shaft fracture
Knee dislocation
Knee sprain
Lightning injury
Mandible fracture
Metacarpal fracture
Metatarsal fracture
Muscle strain
Nasal fracture
Non-accidental trauma
Orbital fracture
Patella fracture
Phalanx fracture (finger)
Proximal humerus fracture
Pulmonary contusion
Rib fracture
Rotator cuff tear (acute traumatic)
Scalp laceration
Scaphoid fracture
Shoulder dislocation
Skull fracture
Splenic laceration
Sternal fracture
Supracondylar pediatric fracture
Tendon laceration (hand:wrist)
Thoracic and lumbar spine fracture
Tibia:fibula fracture
Tibial plateau fracture
Toe fracture
Traumatic epistaxis
Traumatic hyphema
Toxicologic Presentations
Acetaminophen toxicity
Alcohol intoxication
Alcohol withdrawal
Anticholinergic toxicity
Anticoagulant overdose
Benzodiazepine overdose
Benzodiazepine:sedative overdose
Beta-blocker and calcium channel blocker toxicity
Carbon monoxide poisoning
Caustic ingestion
Digoxin toxicity
Drug eruption
Foreign body ingestion
Opioid intoxication
Opioid overdose
Opioid withdrawal
Organophosphate
Salicylate toxicity
Serotonin syndrome
Stimulant intoxication (cocaine, methamphetamine)
Tricyclic antidepressant overdose
Psychiatric Presentations
Acute anxiety
Acute psychosis
Agitation:behavioral emergency
Bipolar disorder
Conversion disorder
Major depressive episode
Neuroleptic malignant syndrome
Suicidal ideation and attempt
Musculoskeletal and Rheumatologic Presentations
Acute low back pain (mechanical)
Bursitis
Cervical radiculopathy
Costochondritis
Gout (acute)
Lumbar radiculopathy
Pseudogout
Tendinitis
Dermatology Presentations
Acute eczema (Eczema acute flare)
Allergic contact dermatitis
Erythema multiforme
Henoch-Schönlein purpura
Pressure injury
Psoriasis (acute flare)
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Urticaria (acute)
Environmental and Exposure Presentations
Envenomation (snake, spider, insect)
High-altitude illness
Hypothermia
Hematologic and Oncologic Presentations
Acute chest syndrome
Coagulopathy
Hyperviscosity syndrome
Sickle cell crisis (vaso-occlusive)
Symptomatic anemia
Thrombocytopenia (severe)
Tumor lysis syndrome
Pediatric-Specific Presentations
Bronchiolitis
Croup
Emergency delivery
Febrile seizure
Kawasaki disease
Neonatal jaundice
Neonatal sepsis
Nursemaid's elbow
Pediatric fever 0 to 28 days
Pediatric fever 29 to 60 days
Pediatric fever 61 to 90 days
Pyloric stenosis
Slipped capital femoral epiphysis
Intussusception
Endocrine and Metabolic Presentations
Adrenal crisis
Diabetic ketoacidosis
Hypercalcemia
Hyperosmolar hyperglycemic state
Hypertensive emergency
Hypertensive urgency
Hypoglycemia
Myasthenia gravis crisis
Myxedema coma
Severe hyperkalemia
Severe hyponatremia
Thyroid storm
ENT and Maxillofacial Presentations
Acute laryngitis
Acute otitis media
Acute pharyngitis
Cerumen impaction
Epistaxis (anterior)
Nasal foreign body
Otitis externa
Tympanic membrane perforation
Ophthalmologic Presentations
Acute angle-closure glaucoma
Central retinal artery occlusion
Chemical eye injury
Corneal abrasion
Corneal ulcer
Globe rupture
Ocular foreign body
Orbital cellulitis
Retinal detachment
Obstetric Presentations
Hyperemesis gravidarum
Painful vaginal bleeding in pregnancy
Placenta previa
Placental abruption
Preeclampsia:eclampsia
Preterm labor
Threatened:inevitable:incomplete abortion
Systemic and Miscellaneous Presentations
Anaphylaxis
Angioedema
Cannabis-induced hyperemesis
Chylothorax
POCUS
Procedures
Calculators
Resuscitation
ECG Guide
Back
Clinical Assessment Checklist
Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Respiratory decompensation from large chylous effusion
▶
SpO2 < 90% on room air
▶
High-flow oxygen initiation
Position upright
Tachypnea >= 30 per minute
▶
Work of breathing assessment
HFNC consideration
Hemodynamic instability
▶
SBP < 90 mmHg or MAP < 65 mmHg
IV access and fluid resuscitation
If massive effusion causing respiratory failure, emergent thoracentesis or chest tube
▶
Rapid decompression priority
Procedural preparation
Stabilization targets
Monitoring and resuscitation targets
▶
SpO2 92-96%
▶
Continuous pulse oximetry
Titrate supplemental oxygen
HR < 100 beats/min
▶
Tachycardia from dehydration or hypovolemia
Fluid replacement as indicated
Nutritional and metabolic targets
▶
Serum albumin trend
Lymphocyte count monitoring for immunosuppression
Chest tube output documentation
▶
Volume per shift
Appearance milky vs serous based on feeding status
Escalation triggers
Criteria for higher-level care
▶
Output > 1 L/day despite dietary modification
▶
High-output leak predicts conservative therapy failure
Interventional radiology or surgical consult trigger
Signs of malnutrition or severe immunosuppression
▶
Albumin < 20 g/L
Lymphopenia < 0.5 x10^9/L
Failure of conservative management beyond 2 weeks
▶
Thoracic duct embolization or surgical ligation planning
Multidisciplinary team activation
New mediastinal mass or rapidly expanding adenopathy
▶
Malignancy (lymphoma) concern
Oncology or hematology consult
Immediate consults
Consultation triggers
▶
Thoracic surgery
▶
Surgical ligation or VATS planning
Refractory or high-output iatrogenic leak
Interventional radiology
▶
Lymphangiography and thoracic duct embolization
When conservative therapy fails after 2 weeks
Hematology or oncology
▶
Lymphoma or malignancy suspected
Flow cytometry or biopsy guidance
Nutrition and dietetics
▶
MCT diet initiation
TPN management when NPO required
History
Presentation pattern
Core symptoms
▶
Dyspnea
▶
Most common presenting symptom (57% of patients)
37% have no respiratory symptoms at presentation
Chest heaviness or pleuritic chest pain
▶
Progressive over days
Related to effusion volume
Fatigue and weight loss
▶
Chronic chyle loss causing catabolism
Malnutrition triad with immunosuppression
Onset and context
Timing and precipitant
▶
Recent thoracic or esophageal surgery
▶
Esophagectomy most common surgical cause
Cardiothoracic or mediastinal procedures
Onset relative to feeding resumption
▶
Postoperative chylothorax typically manifests within days of enteral feeding
Chest tube output > 400 mL/day early postoperative highly concerning
Trauma history
▶
Penetrating thoracic trauma
Spinal hyperflexion or fracture-dislocation
Spontaneous onset without clear precipitant
▶
Malignancy, lymphatic disease, or venous obstruction to consider
Risk factors
Surgical and procedural risks
▶
Esophagectomy
▶
Highest iatrogenic risk
Right-sided injury most common
Congenital heart disease surgery
▶
Major risk in pediatric population
Fontan and other complex repairs
Lung resection, mediastinal instrumentation, spinal surgery
▶
Intraoperative thoracic duct injury
Central venous catheterization and subclavian vein thrombosis
Malignancy risks
▶
Lymphoma
▶
Accounts for 75% of malignant chylothoraces
Night sweats, lymphadenopathy, weight loss clues
Other malignancies with mediastinal involvement
▶
Lung cancer with mediastinal extension
Metastatic disease to mediastinal nodes
Nonmalignant nontraumatic risks
▶
Lymphangioleiomyomatosis
▶
Young women, bilateral lung cysts on CT
TSC gene mutations
Sarcoidosis, cirrhosis, heart failure, nephrotic syndrome
▶
Elevated central venous pressure obstructing thoracic duct
Filariasis in endemic regions
Idiopathic in approximately 9% of cases
Constitutional and systemic review
Malignancy screen symptoms
▶
Night sweats
▶
B-symptom for lymphoma
Fever pattern
Lymphadenopathy
▶
Cervical, supraclavicular, axillary
Mediastinal mass symptom (cough, stridor, SVC syndrome)
Gastrointestinal and lymphatic symptoms
▶
Abdominal distension
▶
Concurrent chylous ascites suggesting extensive lymphatic disruption
Portal hypertension overlap
Peripheral edema
▶
Hypoalbuminemia
Lymphatic obstruction
Past medical and medication history
Relevant prior diagnoses
▶
Known malignancy (especially lymphoma)
▶
Treatment history including chemotherapy or radiation
Disease status
Congenital syndromes
▶
Down syndrome, Noonan syndrome, Turner syndrome associated with chylothorax
Prior congenital heart disease repair
Prior episodes of chylothorax or chylous ascites
▶
Recurrence pattern
Prior management strategies
Medication review
▶
Dasatinib
▶
Reported cause of chylous effusions
Dose and duration
Anticoagulants
▶
Caution if procedural intervention planned
Reversal consideration
Physical Exam
Vitals and general appearance
Hemodynamic snapshot
▶
Tachypnea
▶
Respiratory rate trend
Accessory muscle use
Tachycardia
▶
Dehydration from chyle losses
Large effusion causing mediastinal shift
Hypoxia
▶
SpO2 on room air
Ambulatory desaturation
Nutritional status
▶
Cachexia or muscle wasting
▶
Chronic chyle loss marker
Temporal wasting
Peripheral edema
▶
Hypoalbuminemia
Lymphatic obstruction
Chest examination
Respiratory findings
▶
Decreased breath sounds unilaterally
▶
Right-sided predominance (most thoracic duct is right-sided)
Left-sided if injury at aortic arch level
Dullness to percussion
▶
Effusion localization
Bilateral if bilatreal involvement
Decreased tactile fremitus
▶
Effusion confirmation
Consolidation or atelectasis overlap
Chest tube assessment (postoperative)
▶
Output character
▶
Milky appearance if patient is being fed
May appear serous in fasting or NPO patients
Volume per shift trend
▶
Increasing output with feeding suggests active chyle leak
Lymphatic and abdominal exam
Lymphadenopathy
▶
Cervical and supraclavicular nodes
▶
Lymphoma screen
Virchow node for abdominal malignancy
Axillary and inguinal nodes
▶
Distribution pattern for staging
Tenderness and consistency
Abdominal examination
▶
Ascites
▶
Concurrent chylous ascites
Shifting dullness and fluid wave
Hepatosplenomegaly
▶
Lymphoma infiltration
Portal hypertension from cirrhosis
PITFALLS
Diagnostic pitfalls
▶
Serous-appearing chyle in fasting patients
▶
Triglyceride testing required regardless of appearance
Do not exclude chylothorax based on clear fluid
Bilateral effusions masking unilateral diagnosis
▶
Bilateral sampling if chylothorax suspected
Heart failure and chylothorax may coexist
Differential Diagnosis
Life-threatening diagnoses
Immediate threats requiring exclusion
▶
Hemothorax
▶
ICD-10 J94.2
Hematocrit of pleural fluid > 50% of peripheral hematocrit
Empyema
▶
ICD-10 J86.9
Purulent fluid, positive cultures, foul odor
Esophageal perforation
▶
ICD-10 S27.8
Amylase-rich pleural fluid, food particles, surgical emergency
Malignant pleural effusion with respiratory failure
▶
ICD-10 J91.0
Cytology and biopsy required
Close mimics of chylothorax
Effusion types mimicking chyle
▶
Pseudochylothorax (cholesterol effusion)
▶
ICD-10 J94.8
Cholesterol > 6.47 mmol/L, no chylomicrons
Associated with chronic TB or rheumatoid effusions
Pleural fluid:serum cholesterol ratio > 1.0 distinguishes from chylothorax
Empyema with lipid-laden macrophages
▶
Turbid appearance but clinical infection context
Positive culture and low pH
Parapneumonic effusion
▶
Pneumonia context, low glucose, low pH
No chylomicrons
Nonchylous pleural effusions
▶
Transudative effusions
▶
Heart failure: BNP elevation, bilateral predominance
Hepatic hydrothorax: right-sided, cirrhosis, ascites
Nephrotic syndrome: bilateral, hypoalbuminemia
Exudative effusions
▶
Malignant pleural effusion: cytology positive
Reactive effusion from adjacent infection
Chylothorax etiology differential
Traumatic vs nontraumatic classification
▶
Traumatic and iatrogenic (~54% of cases)
▶
Postoperative most common subtype
Penetrating trauma
Nontraumatic (~46% of cases)
▶
Malignant (lymphoma 75% of malignant cases)
Nonmalignant: lymphangioleiomyomatosis, sarcoidosis, filariasis
Laboratory Tests
Pleural fluid analysis
Diagnostic cornerstone for chylothorax
▶
Triglycerides > 2.87 mmol/L (110 mg/dL)
▶
Highly specific for chylothorax
Sensitivity and specificity > 95%
Triglycerides < 1.37 mmol/L (50 mg/dL)
▶
Chylothorax unlikely (< 5%)
Consider pseudochylothorax if turbid
Chylomicrons on lipoprotein electrophoresis
▶
Pathognomonic for chylothorax
Gold standard confirmatory test
Pleural fluid:serum triglyceride ratio > 1.0
▶
Supports chylothorax diagnosis
Performed when triglycerides in indeterminate range
Pleural fluid:serum cholesterol ratio < 1.0
▶
Distinguishes chylothorax from pseudochylothorax
Cholesterol < 5.18 mmol/L (200 mg/dL) expected in chylothorax
Cell count and differential
Pleural fluid cytology
▶
Lymphocyte-predominant cell count
▶
Often > 80-90% lymphocytes
Exudative by Light's criteria
Flow cytometry if lymphoma suspected
▶
Cell surface markers for B and T cell lineage
Concurrent serum LDH and uric acid
Nutritional and metabolic labs
Protein and nutritional status
▶
Serum albumin
▶
Hypoalbuminemia from chronic chyle loss
Target > 30 g/L for wound healing and immune function
Prealbumin
▶
Short half-life sensitive marker of nutritional recovery
Serial monitoring during treatment
Serum triglycerides fasting
▶
Baseline lipid profile
Comparison to pleural fluid level
Immune function markers
▶
Lymphocyte count
▶
Immunosuppression from chyle loss
Absolute lymphocyte count < 0.5 x10^9/L as severe marker
Immunoglobulin levels
▶
Hypogammaglobulinemia in chronic cases
Infection susceptibility assessment
Metabolic panel and organ function
Standard chemistry
▶
Electrolytes and renal function
▶
Hyponatremia from fluid shifts
Hypokalemia from dietary restriction and losses
LDH and total protein
▶
Light's criteria application
Exudative pattern expected
CBC with differential
▶
Baseline leukocyte count
Anemia from nutritional deficiency
Diagnostic Tests
Scoring Systems
Severity classification by output volume
▶
Low output: < 500 mL/day
▶
Higher likelihood of conservative management success
Dietary modification as first-line
Moderate output: 500-1000 mL/day
▶
Monitor closely for escalation need
Early octreotide consideration
High output: > 1000 mL/day
▶
Associated with higher failure rate of conservative therapy
Interventional radiology or surgical planning
Output >= 12 mL/kg/day after dietary management
▶
Highly predictive of failure of conservative therapy
European Respiratory Journal 2024 consensus threshold
MRI
MR lymphangiography
▶
Nonenhanced MR lymphography
▶
Noninvasive technique
Useful for nontraumatic chylothorax evaluation
Classification of primary lymphatic diseases
Indications
▶
Nontraumatic etiology requiring detailed lymphatic mapping
Planning for thoracic duct embolization
When conventional lymphangiography is not feasible
Protocol details
▶
T2-weighted sequences for lymphatic channels
No radiation exposure
Preferred in pediatric and pregnancy contexts
Findings
▶
Thoracic duct anatomy and leak site localization
Lymphatic obstruction or aplasia patterns
CT
CT chest with contrast
▶
Indications
▶
Recommended for all nontraumatic or unknown etiology chylothoraces
Evaluation for mediastinal masses and lymphadenopathy
Venous obstruction assessment
Treatment planning per ACR Appropriateness Criteria
Findings
▶
Pleural effusion laterality (right > left)
Mediastinal or hilar adenopathy
Primary tumor or metastatic disease
SVC or subclavian vein thrombosis
Limitations
▶
Does not definitively localize thoracic duct leak site
Lymphangiography needed for procedural planning
Ultrasound
Point-of-care ultrasound
▶
Pleural effusion assessment
▶
Effusion size and echogenicity
Loculation or septation identification
Thoracentesis guidance
Cardiac assessment
▶
Right heart strain from large effusion
Pericardial effusion co-identification
Abdominal ultrasound
▶
Concurrent chylous ascites
Hepatosplenomegaly
Lymphadenopathy in retroperitoneum
Lymphoscintigraphy
▶
Indication
▶
Assess thoracic duct patency
Differentiate partial from complete transection
Technique
▶
Radiolabeled colloid injected intradermally into feet
Sequential imaging to track lymphatic flow
Conventional lymphangiography
▶
Indication
▶
Localizes site of chyle leak
Therapeutic embolic effect via ethiodized oil
Success rates
▶
Resolves leaks in 30-70% of cases
Serves as both diagnostic and therapeutic procedure
Disposition
Admission criteria
Inpatient management indications
▶
Virtually all newly diagnosed chylothorax requires admission
▶
Drainage, dietary modification, nutritional monitoring
Etiologic workup with imaging and pleural fluid analysis
ICU-level criteria
▶
Respiratory failure requiring HFNC or mechanical ventilation
Hemodynamic instability
Massive effusion with mediastinal shift
Monitored ward level
▶
High-output leak requiring serial output measurement
Active dietary therapy initiation and monitoring
Consult and transfer
Specialist consultation triggers
▶
Interventional radiology
▶
When conservative therapy fails after approximately 2 weeks
Lymphangiography and thoracic duct embolization planning
Thoracic surgery
▶
Surgical ligation, pleurodesis, or refractory cases
VATS approach when leak site is identifiable
Hematology and oncology
▶
Lymphoma or malignancy suspected
Treatment planning for underlying disease
Nutrition and dietetics
▶
MCT diet counseling and implementation
TPN management when enteral route fails
Discharge criteria
Copy
Criteria for safe discharge
▶
Low-output stable leak on dietary management
▶
Decreasing output trend documented
Patient able to comply with MCT diet at home
Nutritional parameters acceptable
▶
Albumin > 25 g/L
No active malnutrition requiring inpatient support
Underlying etiology addressed or under active follow-up
▶
Malignancy management plan in place
Surgical follow-up arranged if postoperative etiology
Follow-up planning
Copy
Post-discharge monitoring
▶
Repeat chest imaging in 1-2 weeks
▶
Assess for reaccumulation
Document effusion resolution
Serial albumin, prealbumin, lymphocyte count
▶
Nutritional recovery monitoring
Immune function restoration
Diet duration guidance
▶
Traditional recommendation: 6 weeks fat-modified diet
Recent evidence supports as short as 2 weeks in select pediatric populations
Treatment
Initial stabilization
Drainage and fluid replacement
▶
Thoracentesis for symptomatic relief and diagnosis
▶
Diagnostic pleural fluid sample required
Large volume drainage for respiratory compromise
Chest tube insertion for ongoing drainage
▶
High-output or large symptomatic effusion
Serial output monitoring
Fluid and electrolyte replacement
▶
Replace chyle losses with IV fluids
Correct hypokalemia and hyponatremia
Dietary modification (first-line)
Stepwise dietary approach
▶
Low-fat/MCT-only diet as first step
▶
Medium-chain triglycerides absorbed via portal venous system
Bypasses thoracic duct reducing lymphatic flow
Long-chain triglycerides restricted (directly enter enteric lymphatics)
Fat challenge to confirm diagnosis
▶
Increasing fatty intake provokes milky output
Confirms chyle leak diagnostically
Escalation to NPO with TPN if diet fails
▶
Reduces enteric lymphatic flow to minimum
Reserve for high-output leaks or failure of enteral modification
Avoid prolonged NPO/TPN due to associated harms
Pharmacologic therapy
Octreotide
▶
Mechanism
▶
Somatostatin analog
Reduces splanchnic perfusion and GI secretions
Decreases thoracic duct lymph flow
Dosing
▶
50-100 mcg subcutaneous three times daily
Titrate upward based on output response
Adjunctive to dietary therapy per ACR guidelines
Evidence
▶
Improves outcomes when combined with dietary therapy
European Respiratory Journal 2024 multidisciplinary consensus supports use
Monitoring
▶
Serial chest tube output volume and triglyceride content
Glucose monitoring for hyperglycemia side effect
Somatostatin infusion
▶
Mechanism similar to octreotide
▶
IV administration in ICU setting
Dose 250-500 mcg/hour continuous infusion
Alternative when subcutaneous not feasible
▶
Inpatient monitoring required
Titrate to output response
Etilefrine
▶
Alpha-adrenergic agent
▶
Limited evidence in chylothorax
Used in select European centers
Dose 25-50 mg oral three times daily
▶
Cardiac monitoring advised
Not standard of care in all guidelines
Interventional procedures (second-line)
Thoracic duct embolization
▶
Indication
▶
Conservative therapy failure after approximately 2 weeks
High-output leak unresponsive to dietary and pharmacologic management
Technique
▶
Percutaneous approach via intranodal lymphangiography
Ethiodized oil injection to visualize and embolize leak
Outcomes
▶
Clinical success rates 60-97% depending on etiology and technical success
ACR Appropriateness Criteria 2024 update supports as preferred second-line
Contraindications
▶
Complete thoracic duct transection (surgical ligation preferred)
Coagulopathy not corrected
Surgical thoracic duct ligation
▶
Indication
▶
Failed thoracic duct embolization
Identifiable leak site on lymphangiography
High-output iatrogenic chylothorax
Approach
▶
VATS preferred minimally invasive approach
Open thoracotomy if VATS not feasible
Outcomes
▶
Gold standard when leak site is identifiable
Success rate > 80% in iatrogenic cases
Chemical pleurodesis and shunting
Chemical pleurodesis
▶
Indication
▶
Recurrent or refractory chylothorax
Palliation in malignant etiology
Agent
▶
Talc slurry or talc poudrage
Alternatives: doxycycline, bleomycin
Outcomes
▶
Less effective for chylothorax than other effusion types
Considered when surgical or IR approaches not feasible
Pleuroperitoneal shunt
▶
Indication
▶
Last-resort refractory chylothorax
Patient not surgical candidate
Mechanism
▶
Unidirectional valve shunts chyle to peritoneum
Requires patient to pump device manually
Treatment of underlying cause
Etiology-directed therapy
▶
Lymphoma
▶
Systemic chemotherapy as primary treatment
Chylothorax often resolves with lymphoma control
Venous thrombosis
▶
Anticoagulation therapy
SVC or subclavian vein recanalisation
Dasatinib-induced chylothorax
▶
Drug cessation or dose reduction
Pleural effusion typically resolves
Special Populations
Pregnancy
Chylothorax in pregnancy
▶
Epidemiology
▶
Rare but reported; nontraumatic etiology predominates
Lymphangioleiomyomatosis can present or worsen in pregnancy
Physiologic considerations
▶
Increased thoracic pressure from uterus limits pulmonary reserve
Supine hypotension syndrome may worsen hemodynamic compromise
Diagnostic approach
▶
Ultrasound preferred over CT for initial imaging
MR lymphangiography without contrast safe in second and third trimester
CT with shielding if clinically necessary
Treatment modifications
▶
MCT diet and octreotide generally considered safe; limited pregnancy data
TPN viable for nutritional support
Surgical procedures deferred to postpartum when possible
Thoracic duct embolization with ethiodized oil: radiation exposure consideration
Fetal monitoring
▶
Maternal hypoxia and hypoalbuminemia affect fetal growth
Multidisciplinary team including obstetrics
Geriatric
Chylothorax in older adults
▶
Risk profile
▶
Higher prevalence of malignancy (lymphoma) as etiology
More frequent postoperative chylothorax from cardiac and thoracic surgeries
Increased comorbidity burden
Physiologic considerations
▶
Reduced respiratory reserve makes moderate effusions more symptomatic
Hypoalbuminemia from baseline nutritional deficiency common
Immunosenescence amplifies immunosuppression from chyle loss
Diagnostic approach
▶
Standard pleural fluid analysis unchanged
Lower threshold for CT to evaluate malignancy
Treatment considerations
▶
Octreotide dosing unchanged but monitor for bradycardia and hyperglycemia
TPN carries higher risk of line complications and metabolic derangements
Surgical risk stratification required before VATS ligation
Earlier consideration of pleurodesis for palliation in frail patients
Nutritional support
▶
Aggressive nutritional support essential
Dietetics involvement early in course
Pediatrics
Chylothorax in children
▶
Epidemiology
▶
Most common cause: congenital heart disease surgery
Fontan and other complex cardiac repairs major risk
Congenital syndromes: Down, Noonan, Turner syndrome
Congenital chylothorax
▶
Can present in neonates
Associated with hydrops fetalis
Often resolves spontaneously within weeks
Diagnostic approach
▶
Pleural fluid triglycerides and chylomicrons standard
MR lymphangiography preferred over radiation-based imaging
Treatment approach
▶
MCT diet or TPN as first-line
Fat-modified diet duration as short as 2 weeks shown equivalent to 6 weeks in recent pediatric data
Octreotide 1-10 mcg/kg/day subcutaneous or continuous IV
Titrate based on output response and tolerability
Interventional approach
▶
Thoracic duct embolization feasible in older children
Surgical ligation for postoperative cardiac surgery chylothorax refractory to conservative management
Output >= 12 mL/kg/day after dietary management predicts conservative therapy failure
Background
Epidemiology
Incidence and prevalence
▶
Rare condition: approximately 1 per 6,000 hospital admissions
▶
High morbidity and mortality if untreated
Incidence rising with increasing complex cardiothoracic surgery
Etiology distribution
▶
Traumatic and iatrogenic: approximately 54% of cases
Nontraumatic: approximately 46% of cases
Idiopathic: approximately 9% of cases
Malignant subtype
▶
Lymphoma accounts for 75% of malignant chylothoraces
Predominantly non-Hodgkin lymphoma
Laterality
▶
Usually unilateral and right-sided
Left-sided when thoracic duct injury at aortic arch level
Bilateral in approximately 15% of cases
Pathophysiology
Thoracic duct anatomy and physiology
▶
Origin and course
▶
Arises from cisterna chyli at L1-L2 vertebral level
Ascends through posterior mediastinum to the right of aorta
Crosses midline at T4-T5 to left side
Drains into left subclavian-jugular venous junction
Function
▶
Carries dietary fat (chylomicrons) absorbed from intestine
Returns lymph from thorax, abdomen, and lower extremities
Flow 2-4 L/day at baseline; increases substantially with fat ingestion
Mechanisms of disruption
▶
Direct duct disruption
▶
Surgical transection during mediastinal dissection
Traumatic laceration from penetrating injury or hyperflexion
Obstruction causing backpressure leak
▶
Mediastinal tumor compressing duct
Venous thrombosis at duct terminus (SVC or subclavian)
Elevated central venous pressure in heart failure or cirrhosis
Abnormal lymphatic development
▶
Congenital lymphatic anomalies
Lymphangioleiomyomatosis (abnormal smooth muscle proliferation)
Consequences of chyle loss
▶
Metabolic consequences
▶
Protein and fat malnutrition
Electrolyte depletion (sodium, potassium, calcium, bicarbonate)
Hypoalbuminemia and weight loss
Immunologic consequences
▶
Lymphopenia from lymphocyte-rich chyle loss
Hypogammaglobulinemia
Increased infection susceptibility
Therapeutic Considerations
Conservative management outcomes
▶
Success rates by etiology
▶
Traumatic causes: 30-100% resolution with conservative therapy
Higher success when output < 1 L/day
Median resolution with nutritional management approximately 8.7 days
Minimal benefit of conservative therapy in neoplastic etiologies
Duration thresholds for escalation
▶
Persistent leak beyond 2 weeks warrants interventional consideration
Output >= 12 mL/kg/day after dietary modification predicts failure
Interventional outcomes
▶
Thoracic duct embolization
▶
Success rates 60-97% depending on etiology and technical success
Preferred over surgery as less invasive
ACR Appropriateness Criteria 2026 supports as standard second-line
Surgical ligation
▶
Success > 80% in iatrogenic chylothorax
VATS approach associated with lower morbidity
Conventional lymphangiography therapeutic effect
▶
Ethiodized oil embolic effect resolves leaks in 30-70% of cases
Serves as diagnostic and therapeutic simultaneously
ICD-10 classification
▶
Chylothorax: ICD-10 J94.0
▶
SNOMED CT: Chylothorax disorder
Postoperative chylothorax: J95.89
Patient Discharge Instructions
copy discharge instructions
Copy
Your diagnosis and condition
▶
Chylothorax is a buildup of lymphatic fluid (chyle) in the space around your lung
▶
This fluid contains fat, protein, and white blood cells
It can cause breathing difficulty and nutritional problems
Treatment at home requires strict dietary changes
▶
Your medical team has started you on a special diet to reduce fluid production
Follow all dietary instructions exactly as given
Diet instructions
▶
Medium-chain triglyceride (MCT) diet
▶
Use only MCT oil for cooking and fats
Avoid all regular fats, fried foods, full-fat dairy, and oily foods
These regular fats increase fluid production in your chest
If prescribed TPN (nutrition through a vein)
▶
Follow all instructions for line care
Do not eat or drink unless specifically told you can
Duration of diet
▶
Continue the diet for the full duration advised (typically 2-6 weeks)
Do not change to regular diet without speaking to your doctor first
Medications
▶
Octreotide injections if prescribed
▶
Inject at same time each day as instructed
Refrigerate medication
Do not skip doses
All other prescribed medications as directed
▶
Take exactly as prescribed
Do not stop medications without advice
Activity
▶
Avoid heavy lifting and strenuous activity
▶
Increases thoracic pressure and lymph flow
Light walking is acceptable
Elevate head of bed if breathless when lying flat
▶
Upright position helps breathing
Return to emergency department immediately for
▶
Worsening or sudden severe shortness of breath
▶
This may indicate fluid has reaccumulated
Do not wait for your appointment
Chest pain
▶
New or worsening chest pain
Pain with breathing
Fever above 38 degrees Celsius
▶
May indicate infection
Call your doctor or go to emergency
Signs of malnutrition or rapid weight loss
▶
Losing more than 1 kg per week
Extreme weakness or fatigue
Swelling of face or arms
▶
May indicate vein blockage
Requires urgent assessment
Follow-up appointments
▶
Chest imaging in 1-2 weeks
▶
To confirm fluid is not returning
Bring this instruction sheet to appointment
Blood tests as scheduled
▶
Albumin, lymphocyte count, and nutritional markers
Specialist follow-up as arranged
▶
Thoracic surgery, respirology, or oncology as applicable
References
Guidelines and key sources
ACR Appropriateness Criteria on Chylothorax Treatment Planning 2024
▶
Kokabi N, Dabbous H, Khaja MS et al
▶
Journal of the American College of Radiology 2025
Evidence-based imaging and intervention criteria
ACR Appropriateness Criteria Management of Chylothorax 2026
▶
Monroe EJ, Kim CY et al
Journal of the American College of Radiology 2026
European Respiratory Journal Multidisciplinary Consensus 2024
▶
Agrawal A, Chaddha U, Shojaee S et al
▶
Multidisciplinary Management of Adult Patients With Chylothorax
European Respiratory Journal 2024
Comprehensive review references
▶
Bhatnagar M, Fisher A, Ramsaroop S et al
▶
Chylothorax: Pathophysiology, Diagnosis, and Management
Journal of Thoracic Disease 2024
Doerr CH, Allen MS, Nichols FC, Ryu JH
▶
Etiology of Chylothorax in 203 Patients
Mayo Clinic Proceedings 2005
Bender B, Murthy V, Chamberlain RS
▶
The Changing Management of Chylothorax in the Modern Era
European Journal of Cardio-Thoracic Surgery 2016
Supporting references
Pleural disease and effusion references
▶
Feller-Kopman D, Light R
▶
Pleural Disease
New England Journal of Medicine 2018
Shen-Wagner J, Gamble C, MacGilvray P
▶
Pleural Effusion Diagnostic Approach in Adults
American Family Physician 2023
Pediatric references
▶
Büttiker V, Fanconi S, Burger R
▶
Chylothorax in Children: Guidelines for Diagnosis and Management
Chest 1999
Savla JJ, Itkin M, Rossano JW, Dori Y
▶
Post-Operative Chylothorax in Patients With Congenital Heart Disease
Journal of the American College of Cardiology 2017
Winder MM, Vijayarajah S, Reeder RW et al
▶
Successfully Reducing Fat-Modified Diet Duration for Treating Postoperative Chylothorax in Children
Annals of Thoracic Surgery 2022
Imaging references
▶
Cholet C, Delalandre C, Monnier-Cholley L et al
▶
Nontraumatic Chylothorax: Nonenhanced MR Lymphography
Radiographics 2020
Hillerdal G
▶
Chylothorax and Pseudochylothorax
European Respiratory Journal 1997
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.
← Management Protocols
Home
Management Protocols
Chylothorax